[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100454970":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":24,"centralContacts":40,"locations":49,"responsibleParty":67,"collaborators":10,"id":70,"slug":71,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":78,"sex":79,"minAge":80,"maxAge":10,"enrollmentInfo":81,"targetDuration":10,"studyType":84,"phases":10,"briefSummary":85,"conditions":86,"keywords":98,"overallStatus":51,"whyStopped":10,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":109},{"fullName":5,"class":6},"Cedars-Sinai Medical Center","OTHER",[8,12,15,18,21],{"label":9,"type":10,"description":11,"interventionNames":10},"RRMS, SPMS, PPMS, CIS or RIS",null,"Multiple Sclerosis (relapsing-remitting, primary or secondary progressive forms), clinically isolated syndrome, or radiologically isolated syndrome",{"label":13,"type":10,"description":14,"interventionNames":10},"NMOSD","Neuromyelitis optica spectrum disorders",{"label":16,"type":10,"description":17,"interventionNames":10},"MOGAD","Myelin oligodendrocyte glycoprotein antibody disorders",{"label":19,"type":10,"description":20,"interventionNames":10},"Neurological disorder other than MSRD","Neurological disorders due to neurodegenerative, vascular, or headache conditions that are not related to multiple sclerosis or related disorders.",{"label":22,"type":10,"description":23,"interventionNames":10},"Healthy controls","Healthy controls with no known neurological conditions",[25,28,31,33,35,37],{"name":26,"affiliation":5,"role":27},"Omar Al-Louzi, MD","PRINCIPAL_INVESTIGATOR",{"name":29,"affiliation":5,"role":30},"Marwa Kaisey, MD","STUDY_DIRECTOR",{"name":32,"affiliation":5,"role":30},"Brooke Guerrero, MD",{"name":34,"affiliation":5,"role":30},"Laura Locke, CRNP",{"name":36,"affiliation":5,"role":30},"Pascal Sati, PhD",{"name":38,"affiliation":5,"role":39},"Nancy Sicotte, MD","STUDY_CHAIR",[41,45],{"name":26,"role":42,"phone":43,"phoneExt":10,"email":44},"CONTACT","(310) 423-4008","omar.allouzi@cshs.org",{"name":46,"role":42,"phone":47,"phoneExt":10,"email":48},"Group Neurology Research","(310)-423-6472","GroupNeurologyMSProgramResearch@cshs.org",[50],{"facility":5,"status":51,"city":52,"state":53,"zip":54,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":63},"RECRUITING","Los Angeles","California","90048","United States","US",{"type":58,"coordinates":59},"Point",[60,61],-118.24368,34.05223,{"lat":61,"lon":60},[64,66],{"name":26,"role":42,"phone":65,"phoneExt":10,"email":44},"310-423-4008",{"name":46,"role":42,"phone":47,"phoneExt":10,"email":48},{"type":27,"investigatorFullName":68,"investigatorTitle":69,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Omar Al-Louzi","Staff Physician; Director, Visual Outcomes Lab","100454970","ms-researchbiomarkers-100454970",false,"NCT05204459","MS-ResearchBiomarkerS","Investigating the Longitudinal Relationships Between Visual Pathway Injury, Radiological and Blood Biomarkers in Multiple Sclerosis and Related Disorders","MS-ReBS","Inclusion Criteria:\n\n* Subjects who meet any one of the following diagnostic criteria:\n\n  * Diagnosis of MS, CIS,or RIS based on the 2017 revised McDonald criteria.\n  * Diagnosis of NMOSD based on the 2015 revised NMOSD consensus diagnostic criteria.\n  * Diagnosis of myelin oligodendrocyte glycoprotein (MOG)-related encephalomyelitis, optic neuritis, or other associated disease.\n  * Diagnosis of neurological disorders other than MSRD.\n  * Healthy volunteer.\n* Age ≥18.\n* Able to give informed consent.\n\nExclusion Criteria:\n\n* Patients will be excluded from the MRI portions of the study if they have a contraindication to MRI(metallic implantsor foreign bodies, claustrophobia, MRI-incompatible pacemakers, MRI- incompatible prosthetic heart valves).\n* Patients will be excluded from the MRI portions of the study if they are pregnant, but their demographic, clinical information,and disability measures may still be captured under the study.\n* Patients will be excluded from the visual assessment portions of the study if they have had any recent ocular surgery (within the past two months), refractive errors of greater than or equal to ±6 diopters or other eye diseases that may affect or confound OCT\u002FOCTA measurements (ex., age-related macular degeneration, advanced geographic atrophy, diabetic retinopathy, glaucoma).",true,"ALL","18 Years",{"count":82,"type":83},1000,"ESTIMATED","OBSERVATIONAL","This study is being conducted to investigate risk factors for disability progression in Multiple Sclerosis and related disorders (MSRD). The primary goal is to assess whether combining information from visual assessment, blood markers, as well as historical and ongoing longitudinal MRIs of the brain, orbit (the part of the skull where eyes are located), and\u002For spinal cord can predict changes in quantitative disability measures related to MSRD and neurological disease.",[87,88,89,90,91,92,93,94,95,96,97],"Multiple Sclerosis","Multiple Sclerosis, Relapsing-Remitting","Multiple Sclerosis, Primary Progressive","Multiple Sclerosis, Secondary Progressive","Clinically Isolated Syndrome","Radiologically Isolated Syndrome","Neuromyelitis Optica Spectrum Disorders","Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease","Neurologic Autoimmune Disease","Neurologic Disorder","Healthy Aging",[87,88,89,90,91,92,93,99,95,96,97],"Myelin oligodendrocyte glycoprotein antibody-associated disease","2024-02-05",{"date":102,"type":103},"2024-02-06","ACTUAL",{"date":105,"type":103},"2021-11-11",{"date":107,"type":83},"2041-11-11",{"name":5,"class":6},1]